Phosphodiesterase 4: Rethinking cognition in Parkinson disease

Neurology. 2017 Aug 8;89(6):530-531. doi: 10.1212/WNL.0000000000004221. Epub 2017 Jul 12.

Authors

Claudia Jacova¹, Stewart A Factor²

Affiliations

¹ From the School of Graduate Psychology (C.J.), Pacific University, Hillsboro, OR; and Department of Neurology (S.A.F.), Emory School of Medicine, Atlanta, GA. cjacova@pacificu.edu.
² From the School of Graduate Psychology (C.J.), Pacific University, Hillsboro, OR; and Department of Neurology (S.A.F.), Emory School of Medicine, Atlanta, GA.

PMID: 28701498
DOI: 10.1212/WNL.0000000000004221

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cognition
Cognition Disorders*
Cognitive Dysfunction*
Cyclic Nucleotide Phosphodiesterases, Type 4
Humans
Parkinson Disease*

Substances

Cyclic Nucleotide Phosphodiesterases, Type 4